ARGENX SE's ticker is ARGX and the CUSIP is 04016X101. A total of 170 filers reported holding ARGENX SE in Q2 2020. The put-call ratio across all filers is 0.93 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $223,200 | -94.7% | 454 | -95.9% | 0.00% | -95.8% |
Q4 2022 | $4,235,319 | -30.8% | 11,180 | -35.5% | 0.02% | -40.0% |
Q3 2022 | $6,121,000 | +61.4% | 17,338 | +73.2% | 0.04% | +73.9% |
Q2 2022 | $3,792,000 | +1289.0% | 10,009 | +1055.8% | 0.02% | +2200.0% |
Q1 2022 | $273,000 | -33.7% | 866 | -26.4% | 0.00% | -50.0% |
Q4 2021 | $412,000 | +6.2% | 1,176 | -8.6% | 0.00% | 0.0% |
Q3 2021 | $388,000 | -35.2% | 1,286 | -51.6% | 0.00% | -50.0% |
Q2 2020 | $599,000 | -81.2% | 2,658 | -90.5% | 0.00% | -81.8% |
Q3 2019 | $3,189,000 | -51.9% | 27,986 | -40.2% | 0.02% | -47.6% |
Q2 2019 | $6,625,000 | -4.6% | 46,795 | -15.8% | 0.04% | -8.7% |
Q1 2019 | $6,941,000 | +25.9% | 55,600 | -3.1% | 0.05% | +21.1% |
Q4 2018 | $5,512,000 | -1.3% | 57,375 | -22.0% | 0.04% | +18.8% |
Q3 2018 | $5,582,000 | -8.5% | 73,600 | 0.0% | 0.03% | -5.9% |
Q2 2018 | $6,098,000 | +79.8% | 73,600 | +74.6% | 0.03% | +61.9% |
Q1 2018 | $3,391,000 | +66.3% | 42,150 | +30.5% | 0.02% | +75.0% |
Q4 2017 | $2,039,000 | – | 32,300 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Darwin Global Management, Ltd. | 285,198 | $106,259,071 | 29.06% |
Avoro Capital Advisors LLC | 1,287,500 | $479,696,750 | 7.11% |
Paradigm Biocapital Advisors LP | 181,172 | $67,501,064 | 6.40% |
DCF Advisers, LLC | 25,700 | $9,575,310 | 5.86% |
Artia Global Partners LP | 36,404 | $13,563,402 | 5.01% |
Bellevue Group AG | 886,928 | $330,451,634 | 4.80% |
Fairmount Funds Management LLC | 73,526 | $27,394,317 | 4.71% |
Eagle Health Investments LP | 64,400 | $23,994,152 | 4.67% |
Decheng Capital Management III (Cayman), LLC | 27,429 | $10,219,497 | 4.12% |
RTW INVESTMENTS, LP | 482,195 | $179,656,213 | 3.74% |